Radiopharmaceutical Laboratory Services (RLS) MAMC

Amendment / Modification

This amendment modifies Solicitation W81K0226QA015 dated 06 JAN 2026.

• The requirement for Joint Commission accreditation has been removed from the Salient Characteristics.

• The response due date has been extended from 15 Jan 2026 to 10:00 AM Pacific Time on January 23rd, 2026.

• Salient Characteristics section of the solicitation.

• Response Due Date.

• The proposal deadline has been extended to January 23rd, 2026.

• Bidders are no longer required to be Joint Commission accredited.

Solicitation / RFP / RFQ

This document is a solicitation (W81K0226QA0150001) for commercial products and services, specifically related to Radiopharmaceuticals MAMC. The solicitation is issued by W40M MRCO PACIFIC, located at Fort Shafter, HI.

The solicitation details a comprehensive list of radiopharmaceutical products and related services. Key items include various Tc99m compounds (e.g., Tc99m Pertechnetate, Tc99m HDP, Tc99m Pyrophosphate, Tc99m DTPA, Tc99m MAA), I-123 and I-131 compounds, In-111 compounds, Heparin, Kinevac/Sincalide, and WBC collection kits. It also includes delivery services (Weekday, Weekend, Non-Business Hours STAT, Priority Freight) and pharmacist call-out services.

Salient characteristics include:

• Use of only FDA-approved materials and sources.

• Requirement for Joint Commission accreditation.

• Compliance with USP 825 standards.

• Support for "round the clock" customer support.

• Ability to deliver support during weekends and non-business hours.

• Capability to deliver medications under urgent and STAT timelines.

• Safe and responsible delivery services for transporting radioactive material.

• The contract type is not explicitly stated but implies a Firm Fixed Price arrangement for the listed items.

• The period of performance for deliveries is from January 31, 2026, to January 30, 2031.

• The solicitation is set aside as "Unrestricted."

• The offer due date is January 15, 2026, at 10:00 AM.

• Evaluation will be based on the lowest price technically acceptable (LPTA) approach.

• Technical capabilities will be evaluated based on the offeror's ability to meet salient characteristics.

• Price will be evaluated for fairness, reasonableness, and balance.

• The acquisition is listed as "Unrestricted."

• The solicitation includes numerous FAR and DFARS clauses incorporated by reference and in full text, covering various aspects of contract performance, payment, and compliance.

• Delivery locations are specified as AMC MADIGAN LEWIS - MM, FITZSIMMONS, BLDG 9040A, JOINT BASE LEWIS MCCH, WA 98431-1100, UNITED STATES.

Amendment / Modification

This amendment modifies the solicitation W81K0226QA015, originally dated 06 JAN 2026, with an effective date of 07 JAN 2026.

Key changes include modifications to quantities and descriptions for various CLINs/SLINs/ELINs:

• CLIN 0001: Quantity increased from 380 to 445 (+65).
• CLIN 0002: Quantity increased from 1,900 to 2,225 (+325).
• CLIN 0003: Quantity increased from 1,575 to 1,846 (+271).
• CLIN 0004: Quantity increased from 5 to 6 (+1).
• CLIN 0005: Description changed from 'Tc99m Filtered Sulfur Colloid per mCi' (Quantity 100) to 'Tc99m MDP-up to 25 mCi' (Quantity 6), a decrease of 94.
• CLIN 0006: Description changed from 'Tc99m MAG3-up to 10mCi' (Quantity 260) to 'Tc99m DTPA -up to 25mCi' (Quantity 147), a decrease of 113.
• CLIN 0007: Description changed from 'Tc-99m Mebrofenin - up to 10mCi' (Quantity 350) to 'Tc99m DTPA 26-40mCi' (Quantity 147), a decrease of 203.
• CLIN 0008: Description changed from 'Tc99m Myoview-up to 30 mCi' (Quantity 5,550) to 'Tc99m Sulfur Colloid-up to 8 mCi' (Quantity 609), a decrease of 4,941.
• CLIN 0009: Description changed from 'Tc99m Sestamibi-up to 30mCi' (Quantity 5,550) to 'Tc99m MAA -up to 7mCi' (Quantity 206), a decrease of 5,344.
• CLIN 0010: Description changed from 'Tc99m Nephroscan (DMSA) - up to 5 mCi' (Quantity 30) to 'Tc99m MAA Low Particles <200K Particles' (Quantity 6), a decrease of 24.
• CLIN 0011: Description changed from 'UltraTag Kit per vial' (Quantity 150) to 'Tc99m Filtered Sulfur Colloid per mCi' (Quantity 117), a decrease of 33.
• CLIN 0012: Description changed from 'I-123 Nal caps per 100uCi cap' (Quantity 5) to 'Tc99m MAG3-up to 10mCi' (Quantity 304), an increase of 299.
• CLIN 0013: Description changed from 'I-123 Nal caps per 200uCi cap' (Quantity 320) to 'Tc-99m Mebrofenin - up to 10mCi' (Quantity 410), an increase of 90.
• CLIN 0014: Description changed from 'I-123 Nal Compounded cap per mCl' (Quantity 35) to 'Tc99m Myoview-up to 30 mCi' (Quantity 6,500), an increase of 6,465.
• CLIN 0015: Description changed from 'In-111 DTPA per 1.5mci vial' (Quantity 5) to 'Tc99m Sestamibi-up to 30mCi' (Quantity 6,500), an increase of 6,495.
• CLIN 0016: Description changed from 'In-111 Labeled WBC' (Quantity 15) to 'Tc99m Nephroscan (DMSA) - up to 5 mCi' (Quantity 36), an increase of 21.
• CLIN 0017: Description changed from 'I-131 Tx cap First mCi' (Quantity 40) to 'UltraTag Kit per vial' (Quantity 176), an increase of 136.
• CLIN 0018: Description changed from 'I-131 Tx cap ea. additional mCi' (Quantity 3,000) to 'I-123 Nal caps per 100uCi cap' (Quantity 6), a decrease of 2,994.
• CLIN 0019: Description changed from 'Heparin 1000u/ml' (Quantity 15) to 'I-123 Nal caps per 200uCi cap' (Quantity 375), an increase of 360.
• CLIN 0020: Description changed from 'Kinevac / Sincalide per vial' (Quantity 5) to 'I-123 Nal Compounded cap per mCl' (Quantity 42), an increase of 37.
• CLIN 0021: Description changed from 'WBC collection kit' (Quantity 15) to 'In-111 DTPA per 1.5mci vial' (Quantity 6), a decrease of 9.
• CLIN 0022: Description changed from 'Tc99m MDP-up to 25 mCi' (Quantity 5) to 'In-111 Labeled WBC' (Quantity 17), an increase of 12.
• CLIN 0023: Description changed from 'Tc99m DTPA -up to 25mCi' (Quantity 125) to 'I-131 Tx cap First mCi' (Quantity 47), a decrease of 78.
• CLIN 0024: Description changed from 'Tc99m DTPA 26-40mCi' (Quantity 125) to 'I-131 Tx cap ea. additional mCi' (Quantity 3,513), an increase of 3,388.
• CLIN 0025: Description changed from 'Tc99m Sulfur Colloid-up to 8 mCi' (Quantity 520) to 'Heparin 1000u/ml' (Quantity 17), a decrease of 503.
• CLIN 0026: Description changed from 'Tc99m MAA -up to 7mCi' (Quantity 175) to 'Kinevac / Sincalide per vial' (Quantity 6), a decrease of 169.
• CLIN 0027: Description changed from 'Tc99m MAA Low Particles <200K Particles' (Quantity 5) to 'WBC collection kit' (Quantity 17), an increase of 12.
• CLIN 0028: Quantity increased from 5 to 6 (+1).
• CLIN 0029: Quantity increased from 5 to 6 (+1).
• CLIN 0030: Quantity increased from 180 to 211 (+31).
• CLIN 0031: Quantity increased from 180 to 211 (+31).
• CLIN 0032: Quantity increased from 5 to 6 (+1).

Additionally, delivery information for CLINs 0001 through 0032 has been updated. For example, CLIN 0001 delivery quantity changed from 380 to 445, with the delivery period remaining 31 Jan 2026 to 30 Jan 2031.

• Section 11 (This item only applies to amendments of solicitations) is marked as "is not extended."
• Section 14 (Description of Amendment/Modification) details the specific changes to CLINs/SLINs/ELINs and delivery information.

This amendment does not explicitly state a change to the proposal submission deadline or evaluation factors. However, bidders should review the updated quantities and descriptions for all affected CLINs/SLINs/ELINs to ensure their proposals accurately reflect the revised requirements.

Solicitation / RFP / RFQ

This document is a "Combined Synopsis/Solicitation" for Radiopharmaceutical Laboratory Services for Madigan Army Medical Center (MAMC). It solicits proposals for the procurement of various radiopharmaceuticals and related services.

• Procurement of a wide range of radiopharmaceuticals, including Tc99m, I-123, In-111, and I-131 based agents, in various quantities and concentrations.

• Services include delivery of these radiopharmaceuticals, potentially under urgent and STAT timelines.

• Requirements include using only FDA-approved materials and sources, being Joint Commission accredited, and complying with USP 825 standards.

• Support must be available "round the clock" with the ability to deliver during weekends and non-business hours.

• Safe and responsible delivery services in transporting radioactive material are required.

• The solicitation number is W81K0226QA015.

• The period of performance is from January 31, 2026, to January 30, 2031.

• Pricing arrangement is Firm Fixed Price for all listed items.

• The document outlines various FAR and DFARS clauses incorporated by reference and in full text.

• Evaluation will be based on the "lowest price technically acceptable" (LPTA) basis.

• Technical capabilities will be evaluated based on the offeror's ability to meet salient characteristics detailed on pages 7 and 8.

• Price will be evaluated for fairness, reasonableness, and balance.

• Block 10 indicates the acquisition is "UNRESTRICTED" but also lists various set-aside categories (Small Business, Woman-Owned Small Business, Service-Disabled Veteran-Owned Small Business, etc.), suggesting potential for set-aside considerations.

• The document includes detailed lists of radiopharmaceuticals, quantities, delivery schedules, inspection/acceptance locations, and contract clauses.

• The delivery destination for all items is AMC MADIGAN LEWIS - MM, FITZSIMMONS, BLDG 9040A, JOINT BASE LEWIS MCCH, WA 98431-1100, UNITED STATES.

Solicitation / RFP / RFQ

This is a combined synopsis/solicitation for commercial items for Radiopharmaceuticals. The Medical Readiness Contracting Office – Pacific intends to award a firm-fixed price purchase order to the lowest priced responsible quoter whose quotation conforms to the solicitation and is at an evaluated fair and reasonable price.

• The solicitation requires the offeror to complete a line-item pricing structure and provide any additional quote material in company format.

• Offerors must provide all submittals to be considered technically acceptable for award.

• Contract Type: Firm-fixed price purchase order.

• Estimated Ordering Period: January 31, 2026, through January 30, 2031.

• FOB Point: Destination.

• Places of Delivery and Acceptance: Madigan Army Medical Center, Joint Base Lewis-McChord, Washington.

• Quote Submission Deadline: 10:00 AM PDT on Thursday, January 15, 2026.

• Submission Method: Via email to Cindy Means (cindy.j.means.civ@health.mil) and Scott Barr (scott.a.barr.civ@health.mil).

• Evaluation: The government intends to evaluate quotations and award without discussions, based on the lowest priced responsible quoter. However, the government reserves the right to conduct discussions if necessary.

• Offerors must provide a cover page with specific company information (name, address, phone, CAGE Code, Unique Entity ID, POCs).

• NAICS Code: 325412 (Pharmaceutical Preparation and Manufacturing).

• Small Business Size Standard: 1,250 employees.

• PSC Code: 6505 (Drugs and Biologics).

• This announcement constitutes the only solicitation; no written solicitation will be issued.

• FAR Provisions 52.212-1, 52.212-3, 52.212-4, and 52.212-5 apply.

• Offerors are responsible for obtaining necessary licenses and permits.

• The Defense Priorities and Allocations System (DPAS) is not applicable.

• All questions can be sent to the listed POCs.